Sorafenib: Where do we go from here?

Authors

  • Abby B. Siegel,

    Corresponding author
    1. Departments of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NY
    • Center for Liver Disease and Transplantation, NewYork–Presbyterian Hospital, 622 West 168th Street, PH 14 105-C, New York, NY 10032-3784
    Search for more papers by this author
    • fax: 212-305-4343

  • Sonja K. Olsen,

    1. Departments of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NY
    Search for more papers by this author
  • Arthur Magun,

    1. Departments of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NY
    Search for more papers by this author
  • Robert S. Brown Jr

    1. Departments of Medicine and Surgery, Columbia University College of Physicians and Surgeons, New York, NY
    Search for more papers by this author

  • Potential conflict of interest: Dr. Siegel received grants from Bayer, Bristol-Myers Squibb, and Imclone.

Abstract

The approval of sorafenib as the first effective drug for the treatment of hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. A better understanding of HCC pathogenesis has led to the development of several novel targeted treatments. HCC is treated in a uniquely multidisciplinary way requiring surgeons, hepatologists, interventional radiologists, and oncologists. This review describes the molecular pathogenesis of HCC, explores current and future treatments based on these pathways, and describes how these new therapies may augment existing approaches to HCC treatment.(HHEPATOLOGY 2010;)

Ancillary